Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 1/2012

01-07-2012 | Original Article

Modeling and simulation approaches to evaluate pharmacokinetic sampling contamination from central venous catheters in pediatric pharmacokinetic studies of actinomycin-D: a report from the children’s oncology group

Authors: Alena Y. Z. Edwards, Jeffrey M. Skolnik, Erin Dombrowsky, Dimple Patel, Jeffrey S. Barrett

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2012

Login to get access

Abstract

Background

The binding of drugs to catheters can be a source variation in dosing chemotherapeutics. Drug contamination from the dosing central venous line (CVL) can impact the reporting of pharmacokinetic (PK) results and analysis. Peripheral venipuncture avoids binding complications from the CVL but dissuades patients from enrolling. Our group has developed a catheter clearing procedure to minimize the extent of contamination so that dosing and sampling from the CVL can ensue, promoting patient willingness to participate in phase I pediatric oncology trials.

Objectives

To develop a population pharmacokinetic model of actinomycin-D (AMD) in children with cancer incorporating expressions for drug contamination from PK samples obtained via indwelling CVLs and to evaluate the efficiency of a catheter clearing procedure in removing contamination as well as the impact of contamination on PK results.

Methods

A dataset of 199 AMD plasma concentration measurements from 36 patients (age 1.6–20.3 years) was analyzed using nonlinear mixed-effects modeling. Quantitative modeling approaches, including baseline contamination model, covariate model, and catheter clearance model, were evaluated to describe catheter contamination. Monte Carlo simulations mimicking a prospective study in children with cancer were performed to assess the performance of the final model and impact of catheter contamination on PK reporting.

Results

The PK of AMD was best described by a linear 3-compartment model with first-order elimination. A baseline contamination model including a contamination factor proportional to the model-predicted concentration for samples obtained from central catheters was chosen as the most parsimonious and accurate among competing models. The final model parameters were allometrically scaled to a 70 kg person. The estimated mean parameter values were 11 L/h, 5.79, 24.2, 490 L, 17.7, and 42.8 L/h for total clearance, central volume of distribution, peripheral volume 1, peripheral volume 2, inter-compartmental clearance 1, and inter-compartmental clearance 2, respectively. The proportional contamination factor was 19.3 % immediately post-drug administration and decreased at a first-order rate of 0.0932 h−1. Simulations precisely re-estimated kinetic parameters with catheter contamination adjustment. Large uncertainty and poor estimation were observed when contamination was ignored.

Conclusions

Drug contamination from sampling catheter can impact AMD PK results and should be accounted for in the analysis. We provide a framework for evaluating catheter contamination and guidance on adjustment in the PK model.
Appendix
Available only for authorised users
Literature
1.
go back to reference Smith MA, Seibel NL, Altekruse SF et al (2010) Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28(15):2625–2634PubMedCrossRef Smith MA, Seibel NL, Altekruse SF et al (2010) Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28(15):2625–2634PubMedCrossRef
2.
go back to reference Skolnik JM, Zhang AY, Barrett JS et al (2010) Approaches to clear residual chemotherapeutics from indwelling catheters in children with cancer. Ther Drug Monit 32(6):741–748PubMedCrossRef Skolnik JM, Zhang AY, Barrett JS et al (2010) Approaches to clear residual chemotherapeutics from indwelling catheters in children with cancer. Ther Drug Monit 32(6):741–748PubMedCrossRef
3.
go back to reference Veal GJ, Cole M, Errington J et al (2005) Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom children’s cancer study group study. Clin Cancer Res 11(16):5893–5899PubMedCrossRef Veal GJ, Cole M, Errington J et al (2005) Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom children’s cancer study group study. Clin Cancer Res 11(16):5893–5899PubMedCrossRef
4.
go back to reference Mondick JT, Gibiansky L, Gastonguay MR et al (2008) Population pharmacokinetic investigation of actinomycin-D in children and young adults. J Clin Pharmacol 48(1):35–42PubMedCrossRef Mondick JT, Gibiansky L, Gastonguay MR et al (2008) Population pharmacokinetic investigation of actinomycin-D in children and young adults. J Clin Pharmacol 48(1):35–42PubMedCrossRef
5.
6.
go back to reference Patel D, Dombrowsky E, Barrett JS (2010) A SAS-based solution for the extraction of population demographic priors from the CDC’s NHANES survey database: application in the creation of datasets for modeling and simulation projects. J Clin Pharmacol 50(9):1085 Patel D, Dombrowsky E, Barrett JS (2010) A SAS-based solution for the extraction of population demographic priors from the CDC’s NHANES survey database: application in the creation of datasets for modeling and simulation projects. J Clin Pharmacol 50(9):1085
7.
go back to reference Langholz B, Skolnik JM, Barrett JS et al (2011) Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the children’s oncology group. Pediatr Blood Cancer 57(2):252–257PubMedCrossRef Langholz B, Skolnik JM, Barrett JS et al (2011) Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the children’s oncology group. Pediatr Blood Cancer 57(2):252–257PubMedCrossRef
8.
go back to reference Gurney JG, Young JL, Roffers SD et al (1999) Soft tissue sarcomas. In: Ries L, Smith M, Gurney J (eds) Cancer incidence and survival among children and adolescents: United States SEER program 1975–1995. National Cancer Institute, Bethesda Gurney JG, Young JL, Roffers SD et al (1999) Soft tissue sarcomas. In: Ries L, Smith M, Gurney J (eds) Cancer incidence and survival among children and adolescents: United States SEER program 1975–1995. National Cancer Institute, Bethesda
9.
go back to reference Gurney JG, Swensen AR, Bulterys M (1999) Malignant bone tumors. In: Ries L, Smith M, Gurney J (eds) Cancer incidence and survival among children and adolescents: United States SEER program 1975–1995. National Cancer Institute, Bethesda Gurney JG, Swensen AR, Bulterys M (1999) Malignant bone tumors. In: Ries L, Smith M, Gurney J (eds) Cancer incidence and survival among children and adolescents: United States SEER program 1975–1995. National Cancer Institute, Bethesda
10.
go back to reference Leson C, Bryson S, Giesbrecht E et al (1989) Therapeutic monitoring of cyclosporine following pediatric bone marrow transplantation: problems with sampling from silicone central venous lines. Ann Pharmacother 23(4):300–303 Leson C, Bryson S, Giesbrecht E et al (1989) Therapeutic monitoring of cyclosporine following pediatric bone marrow transplantation: problems with sampling from silicone central venous lines. Ann Pharmacother 23(4):300–303
11.
go back to reference Shulman RJ, Ou C, Reed T et al (1998) Central venous catheters versus peripheral veins for sampling blood levels of commonly used drugs. J Parent Enter Nutr 22(4):234–237CrossRef Shulman RJ, Ou C, Reed T et al (1998) Central venous catheters versus peripheral veins for sampling blood levels of commonly used drugs. J Parent Enter Nutr 22(4):234–237CrossRef
12.
go back to reference de Jonge ME, Mathot RAA, van Dam SM et al (2003) Sorption of thiotepa to polyurethane catheter causes falsely elevated plasma levels. Ther Drug Monit 25(3):261–263PubMedCrossRef de Jonge ME, Mathot RAA, van Dam SM et al (2003) Sorption of thiotepa to polyurethane catheter causes falsely elevated plasma levels. Ther Drug Monit 25(3):261–263PubMedCrossRef
13.
go back to reference Puig M (1997) Body composition and growth. In: Walker WA, Watkins JB (eds) Nutrition in pediatrics: basic science and clinical applications. B.C. Decker, Hamilton, pp 44–62 Puig M (1997) Body composition and growth. In: Walker WA, Watkins JB (eds) Nutrition in pediatrics: basic science and clinical applications. B.C. Decker, Hamilton, pp 44–62
Metadata
Title
Modeling and simulation approaches to evaluate pharmacokinetic sampling contamination from central venous catheters in pediatric pharmacokinetic studies of actinomycin-D: a report from the children’s oncology group
Authors
Alena Y. Z. Edwards
Jeffrey M. Skolnik
Erin Dombrowsky
Dimple Patel
Jeffrey S. Barrett
Publication date
01-07-2012
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2012
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-012-1878-y

Other articles of this Issue 1/2012

Cancer Chemotherapy and Pharmacology 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine